title: Clinical experience with ciprofloxacin: analysis of a multi-practice study.
abstract: In a multi-practice study of 113 patients treated with ciprofloxacin (mean daily dosage, 995 mg per day; mean duration of treatment, 9.6 days) for a variety of infections, 14 were microbiologically proven. Of these, bacteriologic cure and/or improvement resulted in 92.9% of cases. For all 113 infections, clinical cure and/or improvement resulted in 97.1% of cases. A total of 17 infections were classified as chronic. Therapy with ciprofloxacin was discontinued in three (2.6%) of 113 patients because of adverse effects. Overall, there were 5/113 (4.4%) adverse reactions (ADRs). Only one ADR was related definitely to ciprofloxacin therapy. Two ADRs were definitely not related; in two the relationship was uncertain. Two patients of the five (40%) elected to continue ciprofloxacin therapy despite mild side effects.
authors.forename: C P
authors.initials: CP
authors.lastname: Dunbar
authors.forename: R L
authors.initials: RL
authors.lastname: Ashton
authors.forename: L
authors.initials: L
authors.lastname: Atkinson
authors.forename: H F
authors.initials: HF
authors.lastname: Crotwell
authors.forename: H M
authors.initials: HM
authors.lastname: Faris
authors.forename: H G
authors.initials: HG
authors.lastname: Royal
authors.forename: D W
authors.initials: DW
authors.lastname: Tyson
authors.forename: C H
authors.initials: CH
authors.lastname: White
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy; D002939:Ciprofloxacin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing
chemical_list: D002939:Ciprofloxacin